Mattesini Alessio, Bartolini Simone, Sorini Dini Carlotta, Valente Serafina, Parodi Guido, Stolcova Miroslava, Meucci Francesco, Di Mario Carlo
Structural Interventional Cardiology Unit, University Of Florence, AOU Careggi, Florence, Italy.
J Thorac Dis. 2017 Aug;9(Suppl 9):S950-S958. doi: 10.21037/jtd.2017.07.25.
The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.
DESolve（美国加利福尼亚州森尼韦尔市的Elixir Medical Corporation公司生产）是一种基于聚L-丙交酯的聚合物支架，表面涂有抗增殖和抗炎药物诺伐莫司。该支架在一年内生物降解，两年内完全吸收，台架试验表明其能够在植入后的关键3至4个月内提供必要的径向强度以支撑血管。DESolve具有独特的自我校正特性，这可能会降低植入后轻微贴壁不良的发生率。DESolve过度扩张是安全的，因为该支架已被证明具有高抗断裂能力。本综述的目的是全面概述关于DESolve的现有临床前和临床数据。
